Clinical Trials
Sep 21, 2026 · 1 min read · 50,734 views
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal
S
Sophia Reyes
Editorial · Sep 21, 2026
Plus news about Amgen, Novartis, Boomray, Merck's Winrevair, Lexeo and Mantle. Ionis and Otsuka tout Phase 3 win in specific type of ALS: Ionis said its Otsuka-partnered drug candidate, ulefnersen,
← Previous
FDA faces questions on 'America First' provisions in latest user fee agreement
Next →
FDA extends review of Exelixis' colorectal cancer drug candidate
